company background image
688091 logo

Shanghai Yizhong Pharmaceutical SHSE:688091 Stock Report

Last Price

CN¥35.92

Market Cap

CN¥7.4b

7D

0.7%

1Y

-1.3%

Updated

07 Feb, 2025

Data

Company Financials

Shanghai Yizhong Pharmaceutical Co., Ltd.

SHSE:688091 Stock Report

Market Cap: CN¥7.4b

688091 Stock Overview

Shanghai Yizhong Pharmaceutical Co., Ltd. More details

688091 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

Shanghai Yizhong Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Yizhong Pharmaceutical
Historical stock prices
Current Share PriceCN¥35.92
52 Week HighCN¥53.18
52 Week LowCN¥20.27
Beta-0.44
1 Month Change2.51%
3 Month Change-17.20%
1 Year Change-1.26%
3 Year Change42.62%
5 Year Changen/a
Change since IPO42.59%

Recent News & Updates

Recent updates

Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%

Nov 20
Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%

We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings

Nov 08
We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings

There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump

Oct 01
There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump

Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?

Aug 20
Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?

What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You

Jul 24
What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You

Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Apr 15
Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Mar 29
Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Shareholder Returns

688091CN PharmaceuticalsCN Market
7D0.7%0.8%1.9%
1Y-1.3%3.4%17.4%

Return vs Industry: 688091 underperformed the CN Pharmaceuticals industry which returned 3.4% over the past year.

Return vs Market: 688091 underperformed the CN Market which returned 17.4% over the past year.

Price Volatility

Is 688091's price volatile compared to industry and market?
688091 volatility
688091 Average Weekly Movement8.5%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement6.6%
10% most volatile stocks in CN Market10.7%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 688091 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688091's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009319Jingsong Zhouwww.yizhongpharma.com

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also develops paclitaxel polymer micelle for the treatment of non-small cell lung cancer. The company was founded in 2009 and is headquartered in Shanghai, China.

Shanghai Yizhong Pharmaceutical Co., Ltd. Fundamentals Summary

How do Shanghai Yizhong Pharmaceutical's earnings and revenue compare to its market cap?
688091 fundamental statistics
Market capCN¥7.36b
Earnings (TTM)CN¥65.60m
Revenue (TTM)CN¥250.66m

112.5x

P/E Ratio

29.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688091 income statement (TTM)
RevenueCN¥250.66m
Cost of RevenueCN¥13.90m
Gross ProfitCN¥236.76m
Other ExpensesCN¥171.16m
EarningsCN¥65.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Apr 23, 2025

Earnings per share (EPS)0.32
Gross Margin94.45%
Net Profit Margin26.17%
Debt/Equity Ratio0.8%

How did 688091 perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

75%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 08:48
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai Yizhong Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.